Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies

Платформа мультиплексного редактирования генома и производства T-клеток для готовых к применению адоптивных T-клеточных иммунотерапевтических препаратов
Martin A. Pulè, Gordon Weng-Kit Cheung, Laurent Poirot, Brian Philip, Cécile Schiffer-Mannioui, Diane Le Clerre, Isabelle Chion-Sotinel, Sophie Derniame, Pierrick Potrel, Cécile Bas, Laëtitia Lemaire, Román Galetto, Céline Lebuhotel, Justin Eyquem, Aymeric Duclert, Agnès Gouble, Sylvain Arnould, Karl S. Peggs, Andrew M. Scharenberg, Julianne N. P. Smith, Cécile Schiffer, Sylvain Arnould
2015-07-16

CAR T-cell immunotherapyCD19 CARMultiplex gene editingOff-the-shelf T-cell therapyTALEN-mediated genome editing
Adoptive immunotherapy using autologous T cells endowed with chimeric antigen receptors (CAR) has emerged as a powerful means of treating cancer. However, a limitation of this approach is that autologous CAR T cells must be generated on a custom-made basis. Here we show that electroporation of transcription activator-like effector nuclease (TALEN) mRNA allows highly efficient multiplex gene editing in primary human T cells. We use this TALEN-mediated editing approach to develop a process for the large-scale manufacturing of T cells deficient in expression of both their αβ T-cell receptor (TCR) and CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent. Functionally, T cells manufactured with this process do not mediate graft-versus-host reactions and are rendered resistant to destruction by alemtuzumab. These characteristics enable the administration of alemtuzumab concurrently or prior to engineered T cells, supporting their engraftment. Furthermore, endowing the TALEN-engineered cells with a CD19 CAR led to efficient destruction of CD19(+) tumor targets even in the presence of the chemotherapeutic agent. These results demonstrate the applicability of TALEN-mediated genome editing to a scalable process, which enables the manufacturing of third-party CAR T-cell immunotherapies against arbitrary targets. As such, CAR T-cell immunotherapies can therefore be used in an "off-the-shelf" manner akin to other biologic immunopharmaceuticals
1
A scalable manufacturing process produces T cells lacking both the αβ T-cell receptor and CD52.
2
Adding a CD19 CAR enables efficient killing of CD19-positive tumor targets despite chemotherapy, supporting third-party, off-the-shelf CAR T-cell immunotherapies.
3
Alemtuzumab administered concurrently with or before engineered T cells can support their engraftment because the cells resist depletion.
4
Electroporation of TALEN mRNA enables highly efficient multiplex genome editing in primary human T cells.
5
TCR-deficient engineered T cells do not mediate graft-versus-host reactions, while CD52 deficiency confers resistance to alemtuzumab-mediated destruction.

large-scale manufactured allogeneic human CAR T cells with multiplex TALEN-mediated disruption of the αβ T-cell receptor and CD52

their graft-versus-host reactivity, resistance to alemtuzumab-mediated destruction, engraftment, and CD19-positive tumor-killing function for off-the-shelf adoptive immunotherapy

Publication Details
Publication Date
2015-07-16
Journal
Publisher
ISSN
Cited by
651
Access Type
Author Information
Authors
Martin A. Pulè
Gordon Weng-Kit Cheung
Laurent Poirot
Brian Philip
Cécile Schiffer-Mannioui
Diane Le Clerre
Isabelle Chion-Sotinel
Sophie Derniame
Pierrick Potrel
Cécile Bas
Laëtitia Lemaire
Román Galetto
Céline Lebuhotel
Justin Eyquem
Aymeric Duclert
Agnès Gouble
Sylvain Arnould
Karl S. Peggs
Andrew M. Scharenberg
Julianne N. P. Smith
Cécile Schiffer
Sylvain Arnould
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%